To assess usefulness of combining splicing changes and mutations to predict drug response, we prioritize FLT3-ITD and Sorafenib and NPM1 and Venetoclax due to reliable mutation calls and their prominent role in AML clinical diagnosis. Here, NPM1 is linked to acute myeloid leukemia.